Второй выпуск интервью с кардиологом из цикла передач "Почта интерниста"
В студии Драпкина Оксана Михайловна - академик РАН, профессор, доктор медицинских наук, заслуженный врач РФ, директор ФГБУ «НМИЦ ТПМ» Минздрава России
При поддержке компании ООО «Новартис Фарма».
Материалы, размещенные на сайте, предназначены только для медицинских и фармацевтических работников. Для распространения на территории РФ.
710541/GENMED/DIG/0923/0
Список использованной литературы:
1. Suga S, Itoh H, Komatsu Y, et al. Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells evidence for CNP as a novel autocrine/paracrine regulator from endothelial cells. Endocrinology. 1993;133:3038–3041.
2. Lee CY, Burnett JC Jr. Natriuretic peptides and therapeutic applications. Heart Fail Rev 2007; 12:131–142).
3. S. Mangiafico, L. C. Costello-Boerrigter, I. A. Andersen et all. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J. 2013 Mar 21; 34 (12): 886–893.
4. Общая характеристика лекарственного препарата Юперио® РУ ЛП-№(002132)-(РГ-RU) от 07.04.2023. URL: 131-02001_Uperio_SmPC_0002_v2_final.pdf / Реестр ЕАЭС, [Электронный ресурс], (обновление в процессе), дата посещения 23.05.2023.
5. L. M. Ruilope, A. Dukat, M. Bohm et all. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010; 375: 1255–66
6. Cavalcante JL, Lima JA, Redheuil A, Al-Mallah MH. Aortic stiffness: current understanding and future directions. J Am Coll Cardiol 2011; 57:1511–1522.
7. Alban Redheuil, Colin O Wu, Nadjia Kachenoura et all. Proximal aortic distensibility is an independent predictor of all-cause mortality and incident CV events. the MESA study. J Am Coll Cardiol 2014; 64:2619–2629.
8. R E Schmieder, F Wagner, M Mayret all. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. European Heart Journal. 2017, 38, 3308–3317.
9. K. Kario, Y. Tamaki, N. Okino et all. LCZ696, a First-in-Class Angiotensin Receptor-Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension. J Clin Hypertens (Greenwich). 2016 Apr; 18(4): 308–314
10. Haiping Du, Xiao Li, Weifang Zhao, Ning Jiang. The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure. Hindawi Journal of Healthcare Engineering Volume 2022, Article ID 9494981, 8 pages
11. Alice M. Jackson, Pardeep S. Jhund, Inder S. Anand et all. Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction European Heart Journal (2021) 42, 3741–3752.
12. B. Williams, J. R. Cockcroft, K. Kario et all. Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension The PARAMETER Study. Hypertension. 2017;69:411–420
13. Izzo JL Jr, Zappe DH, Jia Y, Hafeez K, Zhang J. Efficacy and safety of crystalline valsartan/sacubitril (LCZ696) compared with placebo and combinations of free valsartan and sacubitril in patients with systolic hypertension: the RATIO study. J Cardiovasc Pharmacol. 2017;69(6):374–381
14. Wang TD, Tan RS, Lee HY, et al. Effects of sacubitril/valsartan (LCZ696) on natriuresis, blood pressures, and NT-proBNP in saltsensitive hypertension. Hypertension. 2017;69(1):32–41
15. Sadayoshi Ito, Minoru Satoh, Yuko Tamaki et all. Hypertens Res. 2015 Apr;38(4):269–75.
16. 2. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomized controlled trial. Lancet. 2012;380(9851):1387-95. doi:10.1016/S0140-6736(12)61227-6.
17. Mc Causland F.R. et al. Circulation. 2020;142:1236–1245
18. Solomon, Scott D., et al. "Sacubitril/valsartan across the spectrum of ejection fraction in heart failure." Circulation 141.5 (2020): 352-361.
Добавить в календарь